Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies

Clin Dev Immunol. Jun-Dec 2006;13(2-4):337-47. doi: 10.1080/17402520600800721.

Abstract

The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo. In particular blockade of soluble inflammatory mediators or their corresponding cellular receptors was proven an effective way to regulate inflammation and/or prevent its negative consequences. However, one problem that comes along with an effective neutralization of inflammatory mediators is the general systemic immunomodulatory effect. It is therefore important to design a treatment regimen in a way to strike at the right place and at the right time in order to achieve maximal effects with minimal duration of immunosuppression or hyperactivation. In this review we reflect on two examples of how short time administration of such neutralizing antibodies can block two distinct inflammatory consequences of viral infection. First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use*
  • Chronic Disease / therapy
  • Diabetes Mellitus, Type 1 / etiology
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / therapy*
  • Diabetes Mellitus, Type 1 / virology
  • Humans
  • Immunotherapy
  • Virus Diseases / complications
  • Virus Diseases / immunology*
  • Virus Diseases / therapy*
  • Virus Diseases / virology

Substances

  • Antibodies, Viral